Home
Live Updates
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer : comparemela.com
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer
Verastem Oncology announced the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 clinical trial evaluating avutometinib plus defactinib in combination with gemcitabine...
Related Keywords
Chicago ,
Illinois ,
United States ,
American ,
,
Eastern Cooperative Oncology Group ,
American Society Of Clinical Oncology ,
Verastem Oncology ,
American Society ,
Clinical Oncology ,
Annual Meeting ,
Performance Status ,
comparemela.com © 2020. All Rights Reserved.